[1] Kim YS, Hwang J, Jang JH, et al. Trapa japonica pericarp extract reduces LPS-induced inflammation in macrophages and acute lung injury in mice[J]. Molecules, 2016, 21(3): 392.[2] Atabai K, Matthay MA. The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology[J]. Thorax, 2002, 57(5): 452-458.[3] Thomas G, Kamran A, Pierre HJ, et al. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1 β-dependent mechanism[J].Am J Respir Crit Care Med, 2001,163(6):1384-1388.[4] Gao M, Xie B, Gu C, et al. Targeting the proinflammatory cytokine tumor necrosis factor-alpha to alleviate cardiopulmonary bypass-induced lung injury (review)[J]. Mol Med Rep,2015, 11(4): 2373-2378.[5] Merrill JC, You J, Constable C, et al. Whole-body deletion of LPS-induced TNF-alpha factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis[J]. Proc Natl Acad Sci U S A, 2011, 108(52): 21247-21252.[6] Wang W, Guan WJ, Huang RQ, et al. Carbocisteine attenuates TNF-alpha-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-kappaB and ERK1/2 MAPK signaling pathways[J]. Acta Pharmacol Sin, 2016,doi:10.1038/aps.2015.150.[7] Maloney JP, Gao L. Proinflammatory cytokines increase vascular endothelial growth factor expression in alveolar epithelial cells[J]. Mediat Inflamm, 2015, 2015: 1-7.[8] Chen Y, Chang L, Li W, et al. Thioredoxin protects fetal type Ⅱ epithelial cells from hyperoxia-induced injury[J]. Pediatr Pulmonol, 2010, 45(12): 1192-1200.[9] Sun X, Liang J, Yao X, et al.The activation of EGFR promotes myocardial tumor necrosis factor- α production and cardiac failure in endotoxemia[J]. Oncotarget,2015,6(34):35478-35495.[10] De S, Zhou H, Desantis D, et al. Erlotinib protects against LPS-induced Endotoxicity because TLR4 needs EGFR to signal[J]. Proc Natl Acad Sci U S A,2015, 112(31): 9680-9685.[11] Sculier JP, Berghmans T, Meert AP. Advances in target therapy in lung cancer[J]. Eur Respir Rev, 2015, 24(135): 23-29.[12] De Greve J, Van Meerbeeck J, Vansteenkiste JF, et al. Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase Ⅱ study in caucasian patients (FIELT)[J]. PLoS One,2016, 11(3): e147599.[13] Tang J, Chen X, Tu W, et al. Propofol inhibits the activation of p38 through up-regulating the expression of annexin A1 to exert its anti-inflammation effect[J]. PLoS One, 2011, 6(12): e27890.[14] Guo H, Suo DW, Zhu HP, et al. Early blood purification therapy of severe acute pancreatitis complicated by acute lung injury[J]. Eur Rev Med Pharmacol Sci, 2016, 20(5): 873-878.[15] Beutler B. TLR4 as the mammalian endotoxin sensor[J]. Curr Top Microbiol Immunol, 2002, 270: 109-120.[16] Fodor RS, Georgescu AM, Cioc AD, et al. Time- and dose-dependent severity of lung injury in a rat model of sepsis[J]. Rom J Morphol Embryol, 2015, 56(4): 1329-1337. |